FDA removed 12 peptides from category 2 in 2026

What actually happened in April 2026

On April 22, 2026, FDA removed 12 peptides from its 503A Category 2 list, the substances it had flagged as raising significant safety risks for compounding. HHS Secretary Robert F. Kennedy Jr has publicly backed broader peptide-compounding access. Removal from Category 2 is a procedural first step, not legalization for compounding.

In April 2026, FDA updated its 503A Categories list, the document that tells compounding pharmacies which bulk drug substances they can work with, and twelve peptides were removed from Category 2. FDA dates that change to April 22, 2026: the safety-risk page where those peptides now sit as withdrawn nominations carries that date, and FDA's categories document dates the companion Category 1 action to the same day [1]. A week earlier, on April 16, 2026, the Federal Register notice that scheduled the July advisory committee meeting and opened its public docket published [2]. HHS Secretary Robert F. Kennedy Jr has publicly supported broader compounding access to these peptides, part of a push the administration had signaled interest in earlier in 2026 [3].

This is the first formal regulatory action on these substances since FDA placed a wave of peptides into Category 2 in 2023, when it determined the nominations for many of them raised safety questions it wanted resolved before compounding could proceed [1]. Regulatory-affairs press covered the filing within a day of publication [3].

The 12 peptides removed from Category 2

• BPC-157: body protection compound, a gut-derived peptide studied for tissue repair.
• TB-500: synthetic fragment of thymosin beta-4, studied for recovery and wound healing.
• GHK-Cu (injectable routes): copper tripeptide studied for skin and connective tissue [5]. Non-injectable GHK-Cu was never in Category 2 and sits on a separate evaluation track.
• Epithalon: tetrapeptide linked to telomerase activation in rodent studies.
• MOTS-c: mitochondrial-derived peptide studied for metabolic function and AMPK signaling (also classified as a metabolic modulator by WADA; see the exercise-mimic peptide guide for context).
• DSIP: delta sleep-inducing peptide, listed on the FDA docket under its designated name, Emideltide, researched for sleep architecture.
• Melanotan II: synthetic melanocortin agonist used off-label for pigmentation.
• KPV: tripeptide derived from alpha-MSH, studied for anti-inflammatory effects.
• LL-37: cathelicidin-derived antimicrobial peptide.
• Semax: ACTH-derived heptapeptide researched as a nootropic in Russia.
• Dihexa: angiotensin IV analog studied in preclinical cognition models.
• PEG-MGF: a pegylated (chemically modified for a longer half-life) form of mechano growth factor, an IGF-1 splice variant studied mainly for muscle repair.

You may see other coverage list MK-677 (ibutamoren) as the twelfth substance. That is incorrect: FDA's own Category 2 list still includes Ibutamoren Mesylate as of its most recent update, so it was never part of this action [1]. The twelfth substance is PEG-MGF. It is also worth being precise about GHK-Cu: only the injectable route was affected by the Category 2 removal.

What "removed from Category 2" doesn't mean

Removal from Category 2 does not make these peptides legal to compound broadly, and it is not FDA approval. Category 1 covers substances still under evaluation, not substances cleared for compounding. Each peptide still needs a Pharmacy Compounding Advisory Committee recommendation and a final FDA rule before it can reach the actual 503A Bulks List.

This is the part almost every social post gets wrong. FDA did not make these peptides legal for compounding on April 22, and none of them are FDA-approved drugs. Here is the actual regulatory ladder, using FDA's own category names [1]:

• Category 1, bulk drug substances under evaluation: FDA has not identified a specific safety red flag, but the substance is not yet on the 503A Bulks List that authorizes compounding. Most nominated peptides sit here while FDA and the PCAC work through the evidence.
• Category 2, bulk drug substances that raise significant safety risks: effectively off-limits for 503A pharmacies. This is where these 12 peptides sat until April 22, 2026.
• Category 3, bulk drug substances nominated without adequate support: the nomination itself lacked enough evidence for FDA to evaluate it further.

None of these three categories is the same thing as the 503A Bulks List, the actual list of substances a licensed 503A pharmacy may compound under prescription. A substance reaches that list only after the Pharmacy Compounding Advisory Committee (PCAC) reviews it and FDA issues a final rule [2]. The April 22 update moved these 12 substances out of Category 2, which is necessary but not sufficient: it clears a safety objection, it does not grant compounding access. Until the PCAC recommends inclusion and FDA finalizes a rule, the peptides sit in an intermediate status, no longer flagged as high-risk, but not yet authorized for compounding either.

What happened on July 23 and 24

The Pharmacy Compounding Advisory Committee met over two days and voted on 7 of the 12 peptides for the 503A Bulks List. It recommended six: BPC-157, KPV, TB-500, MOTS-c, Epithalon, and Semax. It voted down DSIP (Emideltide). The votes are advisory and non-binding, and the remaining five move to a separate meeting expected before the end of February 2027.

The PCAC met over two days at FDA's White Oak Campus in Silver Spring, MD, and voted on whether seven of these substances belong on the 503A Bulks List [2][4].

• Day 1 (July 23): BPC-157, KPV, TB-500, and MOTS-c.
• Day 2 (July 24): DSIP, listed on the docket under its designated name Emideltide, plus Semax and Epithalon.

That is seven substances total, not all twelve. The other five, GHK-Cu (injectable), Melanotan II, LL-37, Dihexa, and PEG-MGF, are not on the July agenda at all. FDA has said it plans a separate PCAC meeting before the end of February 2027 to cover those [1][3].

FDA opened docket FDA-2025-N-6895 for public comment, which closed July 22, 2026; comments filed by July 9 were guaranteed to reach the committee before the meeting [2].

The outcome: the committee recommended six of the seven for the 503A Bulks List. On July 23 it backed BPC-157, KPV, and TB-500, plus MOTS-c. On July 24 it backed Epithalon and Semax, and voted down DSIP (Emideltide), the only one of the seven it declined. FDA's own reviewers had recommended in writing against adding all seven, so on six of them the panel went against the agency's scientists.

PCAC votes are advisory, not binding. A favourable vote does not add a substance to the list, does not make it an approved drug, and does not change what a pharmacy may compound today: FDA decides separately whether to adopt the advice, and any listing then runs through formal rulemaking that takes months. The last five substances will not reach a hearing until the Feb 2027 meeting. Note that only two vote margins were ever reported publicly, BPC-157 and DSIP (Emideltide), both by TIME [6]: no margin was published for KPV, TB-500, MOTS-c, Epithalon or Semax, so treat any figure you see for those five as unsourced. We cover the vote in detail, including which margins are real and what the outcome does and does not change, in the FDA peptide vote explained.

Who this actually affects

503A compounding pharmacies gain operational room to prepare, but most will wait for a PCAC recommendation and a final rule before stocking these substances; 503B outsourcing facilities are unlikely to touch them yet at all. Prescribers see lower compliance risk, not new prescribing authority. Buyers outside licensed pharmacies see no change to their legal exposure today.

Compounding pharmacies (503A and 503B)

503A pharmacies, the ones that prepare patient-specific prescriptions, are the group with the most direct stake. The April 22 Category 2 removal gives them room to start preparing operationally, but most will wait for a PCAC recommendation and a final FDA rule before stocking these substances. 503B outsourcing facilities (the ones that make larger sterile batches for clinics) follow a stricter, separate bulks list and are unlikely to touch these peptides before formal rulemaking is complete.

Practitioners and clinics

Functional-medicine clinics, wellness practices, and licensed prescribers have been operating in a gray zone for years. Category 2 removal doesn't change what a physician can legally prescribe today, but it reduces the compliance risk of maintaining a relationship with a compounding pharmacy that stocks these substances. The bigger shift comes once FDA issues a final rule adding a specific peptide to the 503A Bulks List.

Researchers and biohackers

If you're buying through non-pharmacy channels, research-chemical vendors, overseas suppliers, grey-market resellers, the April 22 update changes essentially nothing about your legal exposure today. Federal law still doesn't authorize non-prescription retail sale of these peptides to consumers. The update does, however, make it more realistic that a licensed compounding pharmacy will be a legal option by late 2026 or 2027, which is a meaningful upgrade over the current sourcing landscape. If you are currently sourcing from grey-market suppliers, our guide to vetting research peptides by COA and HPLC walks through the quality checks that matter regardless of the regulatory environment.

Which of these we cover in depth

Five of our published mastery courses directly cover peptides on this list: BPC-157, GHK-Cu, Melanotan II, Semax, and TB-500, each with chemistry, mechanism, clinical evidence, and safety context. Our Melanotan I course covers a sibling peptide with overlapping receptor biology. None of this course content depends on a peptide's current compounding status.

Five of Peptides Academy's published mastery courses directly cover peptides on the list:

• BPC-157: full course covering chemistry, mechanism, clinical evidence, and safety.
• GHK-Cu: multi-unit course on the copper peptide, including skin and wound-healing applications.
• Melanotan II: mechanism, pigmentation pharmacology, and the distinction from Melanotan I.
• Semax: ACTH-derived heptapeptide, cognitive and neurochemistry track including the regulatory landscape.
• TB-500: synthetic thymosin beta-4 fragment, covering wound healing and tissue-repair research.

Our Melanotan I course covers a sibling peptide (afamelanotide) with overlapping MC1R biology. None of these courses depend on a peptide's current compounding status: the biology, evidence, and safety profile are the same whether or not a compounding pharmacy can legally prepare it yet.

Peptide sourcing checksheet

Once a PCAC recommendation lands, evaluating a compounding pharmacy for the first time gets harder to do carefully, not easier. The checksheet below walks through the licensing, certificate-of-analysis, and documentation questions worth having answered before handing over a prescription. It runs entirely in your browser and takes about two minutes to complete.

Once the PCAC vote lands, a lot of people are going to be evaluating compounding pharmacies for the first time. The checksheet below walks through the quality, licensing, and documentation questions you should have answers to before handing over a prescription. It's free and runs in your browser. If you also plan to bring any of these compounds on a trip, check the traveling with peptides guide for current TSA and customs rules before you pack.